Phase 1/2Terminated
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
- Sponsor
- SecuraBio (Industry)
- Enrollment
- 55 enrolled
- Conditions
- CD20+ Follicular Lymphoma
- Interventions
- Duvelisib; Rituximab; Obinutuzumab
- Ages
- adults, older adults
- Registry
- NCT02391545, EUCTR2014-005459-13
Full record on ClinicalTrials.gov
From the registry
A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
Primary outcomes
- Number of Subjects With Dose Limiting Toxicities (DLTs) - Part 1
- Complete Response Rate (CRR)- Part 2
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started